1-吡啶-4-咪唑啉-2-酮 | 52210-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-吡啶-4-咪唑啉-2-酮
• 英文名称: 1-(4-pyridyl)-2-imidazolidinone
• 英文别名: 1-(pyridin-4-yl)imidazolidin-2-one；1-(pyridin-4-yl)-2-imidazolidinone；1-Pyridin-4-yl-imidazolidin-2-one；1-pyridin-4-ylimidazolidin-2-one
• CAS: 52210-90-9
• 化学式: C₈H₉N₃O
• mdl: MFCD05670705
• 分子量: 163.179
• InChiKey: HKCFTGZESMCKJA-UHFFFAOYSA-N

物化性质

• 熔点：
  210-212°C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-吡啶-4-咪唑啉-2-酮 在 吡啶 、 盐酸羟胺 、 sodium hydride 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-[3-Methyl-5-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]pentyl]-3-(4-pyridyl)imidazolidin-2-one
  参考文献：
  名称：

  Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one Derivatives

  摘要：

  A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.

  DOI：

  10.1021/jm050033v
• 作为产物：
  描述：

  1-(2-氯-乙基)-3-吡啶-4-基-脲 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 2.0h， 以4.07 g的产率得到1-吡啶-4-咪唑啉-2-酮
  参考文献：
  名称：

  吡咯并咪唑啉酮连接的吡咯并[2,1-c] [1,4]苯并二氮杂Con缀合物的合成，DNA结合和抗癌活性

  摘要：

  合成了一系列吡啶基咪唑啉酮连接的吡咯并[2,1-c] [1,4]苯并二氮杂（PBD）缀合物，并评估了它们的DNA结合能力和细胞毒性。这些结合物显示出显着的DNA结合能力和有效的抗癌活性，GI50值在0.2 – 3μM的范围内。

  DOI：

  10.2174/157018012799129927

文献信息

• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• Indolylalkylpiperidines
  申请人：Ciba-Geigy Corporation

  公开号：US04073911A1

  公开（公告）日：1978-02-14

  1-(Indolyl-3-alkyl)-3 or 4-(ureido or guanidino)-piperidines, e.g. those of the formula ##STR1## R= H; alkyl; free, etherified or esterified OH or SH; CF.sub.3, NO.sub.2 or NH.sub.2 m= 1-4; n= 2 or 3; X= O, S or NH acyl derivatives and salts thereof are antihypertensive agents.

  1-(吲哚基-3-烷基)-3或4-(脲基或胍基)-哌啶类化合物，例如式##STR1##中的化合物 R= H；烷基；自由的、醚化的或酯化的羟基或硫醇基；CF.sub.3，NO.sub.2或NH.sub.2 m= 1-4；n= 2或3；X= O，S或NH的酰基衍生物及其盐是降压药物。
• Inhibitors of protein tyrosine kinase activity
  申请人：Raeppel Stephane

  公开号：US20080004273A1

  公开（公告）日：2008-01-03

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，该发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如抑制VEGF受体信号传导和HGF受体信号传导。更具体地，该发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物、组合物和方法。该发明还提供了用于治疗细胞增殖性疾病和病况的组合物和方法。
• Palladium-Catalyzed Site-Selective Amidation of Dichloroazines
  作者：Ian S. Young、Anna-Lena Glass、Theresa Cravillion、Chong Han、Haiming Zhang、Francis Gosselin

  DOI：10.1021/acs.orglett.8b01483

  日期：2018.7.6

  A highly site-selective amidation reaction of substituted 2,4-dichloroazines is reported. Palladium acetate/1,1′-bis(diphenylphosphino)ferrocene (dppf) was identified as the optimal catalyst system, producing >99:1 C-2/C-4 selectivity for most examples. The generality of this transformation was demonstrated through a survey of a diverse amide/substituted 2,4-dichloroazine scope, leading to the preparation

  报道了取代的2，4-二氯嗪的高度位点选择性酰胺化反应。乙酸钯/ 1,1'-双（二苯基膦基）二茂铁（dppf）被确定为最佳催化剂体系，在大多数实例中，其生成的C> 2 / C-4选择性> 99：1。通过各种酰胺/取代的2,4-二氯嗪范围的调查证明了这种转化的一般性，从而以良好至极好的收率制备了所需的C-2酰胺化产品。
• Imidazolidinone compounds
  申请人：——

  公开号：US20030087936A1

  公开（公告）日：2003-05-08

  A compound having the formula: 1 in which R 1 , R 2 , R 3 , T, W, m, x, and y are defined as in the specification. Also disclosed is a method of treating enterovirus infection by using a compound described above.

  一个具有以下式子的化合物：1，其中R1、R2、R3、T、W、m、x和y的定义如规范中所述。还公开了一种利用上述化合物治疗肠道病毒感染的方法。